Autoimmune Channelopathies and Related Neurological Disorders

Neuron

Volumn 52, Issue 1, 2006, Pages 123-138

  Vincent, Angela ^a   Lang, Bethan ^a   Kleopa, Kleopas A ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; ION CHANNEL; LIGAND; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

ANTIBODY SPECIFICITY; AUTOIMMUNE DISEASE; AUTONOMIC NEUROPATHY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DISEASE ACTIVITY; DISEASE ASSOCIATION; EATON LAMBERT SYNDROME; EPILEPSY; EVIDENCE BASED MEDICINE; GANGLION; GENETIC DISORDER; HUMAN; MEDICAL INFORMATION; MEDICAL RESEARCH; MOLECULAR DYNAMICS; MORVAN SYNDROME; MYASTHENIA GRAVIS; MYOKYMIA; NERVE CELL; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NONHUMAN; PARANEOPLASTIC NEUROPATHY; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; RARE DISEASE; REVIEW; SIGNAL PROCESSING; SLEEP DISORDER; SYNAPTIC TRANSMISSION; SYNDROME; THYMUS;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; HUMANS; ION CHANNELS; MODELS, NEUROLOGICAL; NERVOUS SYSTEM DISEASES; NEUROMUSCULAR JUNCTION;

EID: 33749049955     PISSN: 08966273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuron.2006.09.024     Document Type: Review

References (169)

1. Antozzi C., Frassoni C., Vincent A., Regondi M.C., Andreetta F., Bernasconi P., Ciano C., Chang T., Cornelio F., Spreafico R., and Mantegazza R. Sequential antibodies to potassium channels and glutamic acid decarboxylase in neuromyotonia. Neurology 64 (2005) 1290-1293
2. Arimura K., Arimura Y., Ng A., Uehara A., Nakae M., Osame M., and Stalberg E. The origin of spontaneous discharges in acquired neuromyotonia. A Macro EMG study. Clin. Neurophysiol. 116 (2005) 1835-1839
3. Arroyo E.J., and Scherer S.S. On the molecular architecture of myelinated fibers. Histochem. Cell Biol. 113 (2000) 1-18
4. Asher O., Kues W.A., Witzemann V., Tzartos S.J., Fuchs S., and Souroujon M.C. Increased gene expression of acetylcholine receptor and myogenic factors in passively transferred experimental autoimmune myasthenia gravis. J. Immunol. 151 (1993) 6442-6450
5. Barber P.A., Anderson N.E., and Vincent A. Morvan's syndrome associated with voltage-gated K+ channel antibodies. Neurology 54 (2000) 771-772
6. Barrett-Jolley R., Byrne N., Vincent A., and Newsom-Davis J. Plasma from patients with seronegative myasthenia gravis inhibit nAChR responses in the TE671/RD cell line. Pflugers Arch. 428 (1994) 492-498
7. Bataller L., and Dalmau J.O. Paraneoplastic disorders of the central nervous system: update on diagnostic criteria and treatment. Semin. Neurol. 24 (2004) 461-471
8. Beeson D., Higuchi O., Palace J., Cossins J., Spearman H., Maxwell S., Newsom-Davis J., Burke G., Fawcett P., Motomura M., et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science (2006) 10.1126/science.1130837 Published online August 17, 2006
9. Benveniste O., Jacobson L., Farrugia M.E., Clover L., and Vincent A. MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo. J. Neuroimmunol. 170 (2005) 41-48
10. Bien C.G., Granata T., Antozzi C., Cross J.H., Dulac O., Kurthen M., Lassmann H., Mantegazza R., Villemure J.G., Spreafico R., and Elger C.E. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain 128 (2005) 454-471
11. Browne D.L., Gancher S.T., Nutt J.G., Brunt E.R., Smith E.A., Kramer P., and Litt M. Episodic ataxia/myokymia syndrome is associated with point mutations in the human potassium channel gene, KCNA1. Nat. Genet. 8 (1994) 136-140
12. Buchwald B., Ahangari R., Weishaupt A., and Toyka K.V. Presynaptic effects of immunoglobulin G from patients with Lambert-Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Muscle Nerve 31 (2005) 487-494
13. Buckley C., and Vincent A. Autoimmune channelopathies. Nat. Clin. Pract. Neurol. 1 (2005) 22-33
14. Buckley C., Oger J., Clover L., Tuzun E., Carpenter K., Jackson M., and Vincent A. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann. Neurol. 50 (2001) 73-78
15. Bufler J., Pitz R., Czep M., Wick M., and Franke C. Purified IgG from seropositive and seronegative patients with mysasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels. Ann. Neurol. 43 (1998) 458-464
16. Burges J., Wray D.W., Pizzighella S., Hall Z., and Vincent A. A myasthenia gravis plasma immunoglobulin reduces miniature endplate potentials at human endplates in vitro. Muscle Nerve 13 (1990) 407-413
17. Burges J., Vincent A., Molenaar P.C., Newsom-Davis J., Peers C., and Wray D. Passive transfer of seronegative myasthenia gravis to mice. Muscle Nerve 17 (1994) 1393-1400
18. Catterall W.A. Structure and function of voltage-sensitive ion channels. Science 242 (1988) 50-61
19. Chung Y.H., Shin C., Kim M.J., Lee B.K., and Cha C.I. Immunohistochemical study on the distribution of six members of the Kv1 channel subunits in the rat cerebellum. Brain Res. 895 (2001) 173-177
20. Compston D.A., Vincent A., Newsom-Davis J., and Batchelor J.R. Clinical, pathological, HLA antigen and immunological evidence for disease heterogeneity in myasthenia gravis. Brain 103 (1980) 579-601
21. Corrette B.J., Repp H., Dreyer F., and Schwarz J.R. Two types of fast K+ channels in rat myelinated nerve fibres and their sensitivity to dendrotoxin. Pflugers Arch. 418 (1991) 408-416
22. Dalton P., Deacon R., Blamire A., Pike M., McKinlay I., Stein J., Styles P., and Vincent A. Maternal neuronal antibodies associated with autism and a language disorder. Ann. Neurol. 53 (2003) 533-537
23. Dalton P., Clover L., Wallerstein R., Stewart H., Genzel-Boroviczeny O., Dean A., and Vincent A. Fetal arthrogryposis and maternal serum antibodies. Neuromuscul. Disord. 16 (2006) 481-491
24. DeGiorgio L.A., Konstantinov K.N., Lee S.C., Hardin J.A., Volpe B.T., and Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat. Med. 7 (2001) 1189-1193
25. Devaux J., Alcaraz G., Grinspan J., Bennett V., Joho R., Crest M., and Scherer S.S. Kv3.1b is a novel component of CNS nodes. J. Neurosci. 23 (2003) 4509-4518
26. Devaux J.J., Kleopa K.A., Cooper E.C., and Scherer S.S. KCNQ2 is a nodal K+ channel. J. Neurosci. 24 (2004) 1236-1244
27. Doyle D.A., Morais Cabral J., Pfuetzner R.A., Kuo A., Gulbis J.M., Cohen S.L., Chait B.T., and MacKinnon R. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 280 (1998) 69-77
28. Drachman D.B. Myasthenia gravis. N. Engl. J. Med. 330 (1994) 1797-1810
29. Drachman D.B., Angus C.W., Adams R.N., Michelson J.D., and Hoffman G.J. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. N. Engl. J. Med. 298 (1978) 1116-1122
30. Drachman D.B., Adams R.N., Josifek L.F., and Self S.G. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N. Engl. J. Med. 307 (1982) 769-775
31. Eaton L.M., and Lambert E.H. Electromyography and electric stimulation of nerves in diseases of motor unit; observations on myasthenic syndrome associated with malignant tumors. JAMA 163 (1957) 1117-1124
32. Elmqvist D., and Lambert E.H. Detailed analysis of neuromuscular transmission in a patient with the myasthenic syndrome sometimes associated with bronchogenic carcinoma. Mayo Clin. Proc. 43 (1968) 689-713
33. Engel A.G., Lambert E.H., and Howard F.M. Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. Mayo Clin. Proc. 52 (1977) 267-280
34. Engel A.G., Nagel A., Fukuoka T., Fukunaga H., Osame M., Lang B., Newsom-Davis J., Vincent A., Wray D.W., and Peers C. Motor nerve terminal calcium channels in Lambert-Eaton myasthenic syndrome. Morphologic evidence for depletion and that the depletion is mediated by autoantibodies. Ann. NY Acad. Sci. 560 (1989) 278-290
35. Eunson L.H., Rea R., Zuberi S.M., Youroukos S., Panayiotopoulos C.P., Liguori R., Avoni P., McWilliam R.C., Stephenson J.B., Hanna M.G., et al. Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann. Neurol. 48 (2000) 647-656
36. Fambrough D.M., Drachman D.B., and Satyamurti S. Neuromuscular junction in myasthenia gravis: decreased acetylcholine receptors. Science 182 (1973) 293-295
37. Farrugia M.E., Robson M.D., Clover L., Anslow P., Newsom-Davis J., Kennett R., Hilton-Jones D., Matthews P.M., and Vincent A. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 129 (2006) 1481-1492
38. Fukunaga H., Engel A.G., Lang B., Newsom-Davis J., and Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc. Natl. Acad. Sci. USA 80 (1983) 7636-7640
39. Fukuoka T., Engel A.G., Lang B., Newsom-Davis J., Prior C., and Wray D.W. Lambert-Eaton myasthenic syndrome: I. Early morphological effects of IgG on the presynaptic membrane active zones. Ann. Neurol. 22 (1987) 193-199
40. Fukuoka T., Engel A.G., Lang B., Newsom-Davis J., and Vincent A. Lambert-Eaton myasthenic syndrome: II. Immunoelectron microscopy localization of IgG at the mouse motor end-plate. Ann. Neurol. 22 (1987) 200-211
41. Giovannini F., Sher E., Webster R., Boot J., and Lang B. Calcium channel subtypes contributing to acetylcholine release from normal, 4-aminopyridine-treated and myasthenic syndrome auto-antibodies-affected neuromuscular junctions. Br. J. Pharmacol. 136 (2002) 1135-1145
42. Glass D.J. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat. Cell Biol. 5 (2003) 87-90
43. Graus F., Lang B., Pozo-Rosich P., Saiz A., Casamitjana R., and Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology 59 (2002) 764-766
44. Guyon T., Wakkach A., Poea S., Mouly V., Klingel-Schmitt I., Levasseur P., Beeson D., Asher O., Tzartos S., and Berrih-Aknin S. Regulation of acetylcholine receptor gene expression in human myasthenia gravis muscles. Evidences for a compensatory mechanism triggered by receptor loss. J. Clin. Invest. 102 (1998) 249-263
45. Halbach M., Homberg V., and Freund H.J. Neuromuscular, autonomic and central cholinergic hyperactivity associated with thymoma and acetylcholine receptor-binding antibody. J. Neurol. 234 (1987) 433-436
46. Hart I.K., Waters C., Vincent A., Newland C., Beeson D., Pongs O., Morris C., and Newsom-Davis J. Autoantibodies detected to expressed K+ channels are implicated in neuromyotonia. Ann. Neurol. 41 (1997) 238-246
47. Hart I.K., Maddison P., Newsom-Davis J., Vincent A., and Mills K.R. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain 125 (2002) 1887-1895
48. Heidenreich F., and Vincent A. Antibodies to ion-channel proteins in thymoma with myasthenia, neuromyotonia, and peripheral neuropathy. Neurology 50 (1998) 1483-1485
49. Heinemann S., Bevan S., Kullberg R., Lindstrom J., and Rice J. Modulation of acetylcholine receptor by antibody against the receptor. Proc. Natl. Acad. Sci. USA 74 (1977) 3090-3094
50. Hoch W., McConville J., Helms S., Newsom-Davis J., Melms A., and Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat. Med. 7 (2001) 365-368
51. Hoedemaekers A., Bessereau J.L., Graus Y., Guyon T., Changeux J.P., Berrih-Aknin S., van Breda Vriesman P., and De Baets M.H. Role of the target organ in determining susceptibility to experimental autoimmune myasthenia gravis. J. Neuroimmunol. 89 (1998) 131-141
52. Iranzo A., Graus F., Clover L., Morera J., Bruna J., Vilar C., Martinez-Rodriguez J.E., Vincent A., and Santamaria J. Rapid eye movement sleep behavior disorder and potassium channel antibody-associated limbic encephalitis. Ann. Neurol. 59 (2006) 178-181
53. Isaacs H., and Heffron J.J. The syndrome of 'continuous muscle-fibre activity' cured: further studies. J. Neurol. Neurosurg. Psychiatry 37 (1974) 1231-1235
54. Ito Y., Miledi R., Vincent A., and Newsom-Davis J. Acetylcholine receptors and end-plate electrophysiology in myasthenia gravis. Brain 101 (1978) 345-368
55. Jacobson L., Polizzi A., Morriss-Kay G., and Vincent A. Plasma from human mothers of fetuses with severe arthrogryposis multiplex congenita causes deformities in mice. J. Clin. Invest. 103 (1999) 1031-1038
56. Jahn K., Franke C., and Bufler J. Mechanism of block of nicotinic acetylcholine receptor channels by purified IgG from seropositive patients with myasthenia gravis. Neurology 54 (2000) 474-479
57. Jan L.Y., and Jan Y.N. Voltage-gated and inwardly rectifying potassium channels. J. Physiol. 505 (1997) 267-282
58. Jha S., Xu K., Maruta T., Oshima M., Mosier D.R., Atassi M.Z., and Hoch W. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (MuSK). J. Neuroimmunol. 175 (2006) 107-117
59. Johnston D., Hoffman D.A., Magee J.C., Poolos N.P., Watanabe S., Colbert C.M., and Migliore M. Dendritic potassium channels in hippocampal pyramidal neurons. J. Physiol. 525 (2000) 75-81
60. 1A-subunit. Proc. Natl. Acad. Sci. USA 96 (1999) 15245-15250
61. Kaminski H.J. Acetylcholine receptor epitopes in ocular myasthenia. Ann. N Y Acad. Sci. 841 (1998) 309-319
62. Kaminski H.J., Li Z., Richmonds C., Lin F., and Medof M.E. Complement regulators in extraocular muscle and experimental autoimmune myasthenia gravis. Exp. Neurol. 189 (2004) 333-342
63. Kleopa K.A., and Barchi R.L. Genetic disorders of neuromuscular ion channels. Muscle Nerve 26 (2002) 299-325
64. Kleopa K.A., Elman L.B., Lang B., Vincent A., and Scherer S.S. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations. Brain 129 (2006) 1570-1584
65. Kowal C., DeGiorgio L.A., Nakaoka T., Hetherington H., Huerta P.T., Diamond B., and Volpe B.T. Cognition and immunity; antibody impairs memory. Immunity 21 (2004) 179-188
66. Kurono A., Arimura K., Watanabe O., Tomimitsu H., Nagado T., Sonoda Y., Kameyama M., and Osame M. IgM-containing fraction suppressed voltage-gated potassium channels in acquired neuromyotonia. Acta Neurol. Scand. 113 (2006) 185-188
67. Kusner L.L., and Kaminski H.J. Nitric oxide synthase is concentrated at the skeletal muscle endplate. Brain Res. 730 (1996) 238-242
68. Lambert E.H., and Elmqvist D. Quantal components of end-plate potentials in the myasthenic syndrome. Ann. N Y Acad. Sci. 183 (1971) 183-199
69. Lance J.W., Burke D., and Pollard J. Hyperexcitability of motor and sensory neurons in neuromyotonia. Ann. Neurol. 5 (1979) 523-532
70. Lang B., Newsom-Davis J., Peers C., Prior C., and Wray D.W. The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse. J. Physiol. 390 (1987) 257-270
71. Lee E.K., Maselli R.A., Ellis W.G., and Agius M.A. Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma. J. Neurol. Neurosurg. Psychiatry 65 (1998) 857-862
72. Lennon V.A., Kryzer T.J., Griesmann G.E., O'Suilleabhain P.E., Windebank A.J., Woppmann A., Miljanich G.P., and Lambert E.H. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N. Engl. J. Med. 332 (1995) 1467-1474
73. Lennon V.A., Ermilov L.G., Szurszewski J.H., and Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J. Clin. Invest. 111 (2003) 907-913
74. Lennon V.A., Kryzer T.J., Pittock S.J., Verkman A.S., and Hinson S.R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202 (2005) 473-477
75. Levite M., and Hermelin A. Autoimmunity to the glutamate receptor in mice-a model for Rasmussen's encephalitis?. J. Autoimmun. 13 (1999) 73-82
76. Liguori R., Vincent A., Clover L., Avoni P., Plazzi G., Cortelli P., Baruzzi A., Carey T., Gambetti P., Lugaresi E., and Montagna P. Morvan's syndrome: peripheral and central nervous system and cardiac involvement with antibodies to voltage-gated potassium channels. Brain 124 (2001) 2417-2426
77. Lindstrom J.M., Seybold M.E., Lennon V.A., Whittingham S., and Duane D.D. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 26 (1976) 1054-1059
78. Losen M., Stassen M.H., Martinez-Martinez P., Machiels B.M., Duimel H., Frederik P., Veldman H., Wokke J.H., Spaans F., Vincent A., and De Baets M.H. Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis. Brain 128 (2005) 2327-2337
79. 2+ channel inhibitors in venom of the spider Plectreurys tristis. Toxicon 31 (1993) 1249-1256
80. MacKinnon R. Determination of the subunit stoichiometry of a voltage-activated potassium channel. Nature 350 (1991) 232-235
81. MacLennan C., Beeson D., Buijs A.M., Vincent A., and Newsom-Davis J. Acetylcholine receptor expression in human extraocular muscles and their susceptibility to myasthenia gravis. Ann. Neurol. 41 (1997) 423-431
82. Maddison P., Mills K.R., and Newsom-Davis J. Clinical electrophysiological characterization of the acquired neuromyotonia phenotype of autoimmune peripheral nerve hyperexcitability. Muscle Nerve 33 (2006) 801-808
83. Madrid A., Gil-Peralta A., Gil-Neciga E., Gonzalez J.R., and Jarrin S. Morvan's fibrillary chorea: remission after plasmapheresis. J. Neurol. 243 (1996) 350-353
84. Manganas L.N., and Trimmer J.S. Subunit composition determines Kv1 potassium channel surface expression. J. Biol. Chem. 275 (2000) 29685-29693
85. Mantegazza R., Bernasconi P., Baggi F., Spreafico R., Ragona F., Antozzi C., Bernardi G., and Granata T. Antibodies against GluR3 peptides are not specific for Rasmussen's encephalitis but are also present in epilepsy patients with severe, early onset disease and intractable seizures. J. Neuroimmunol. 131 (2002) 179-185
86. Marx A., Wilisch A., Schultz A., Gattenlohner S., Nenninger R., and Muller-Hermelink H.K. Pathogenesis of myasthenia gravis. Virchows Arch. 430 (1997) 355-364
87. McConville J., Farrugia M.E., Beeson D., Kishore U., Metcalfe R., Newsom-Davis J., and Vincent A. Detection and characterization of MuSK antibodies in seronegative myasthenia gravis. Ann. Neurol. 55 (2004) 580-584
88. McNamara J.O., Whitney K.D., Andrews P.I., He X.P., Janumpalli S., and Patel M.N. Evidence for glutamate receptor autoimmunity in the pathogenesis of Rasmussen encephalitis. Adv. Neurol. 79 (1999) 543-550
89. Mesnard-Rouiller L., Bismuth J., Wakkach A., Poea-Guyon S., and Berrih-Aknin S. Thymic myoid cells express high levels of muscle genes. J. Neuroimmunol. 148 (2004) 97-105
90. Monaghan M.M., Trimmer J.S., and Rhodes K.J. Experimental localization of Kv1 family voltage-gated K+ channel alpha and beta subunits in rat hippocampal formation. J. Neurosci. 21 (2001) 5973-5983
91. Mossman S., Vincent A., and Newsom-Davis J. Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity. Lancet 1 (1986) 116-119
92. Motomura M., Johnston I., Lang B., Vincent A., and Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J. Neurol. Neurosurg. Psychiatry 58 (1995) 85-87
93. Nagado T., Arimura K., Sonoda Y., Kurono A., Horikiri Y., Kameyama A., Kameyama M., Pongs O., and Osame M. Potassium current suppression in patients with peripheral nerve hyperexcitability. Brain 122 (1999) 2057-2066
94. Newsom-Davis J., and Mills K.R. Immunological associations of acquired neuromyotonia (Isaacs' syndrome). Report of five cases and literature review. Brain 116 (1993) 453-469
95. Newsom-Davis J., Pinching A.J., Vincent A., and Wilson S.G. Function of circulating antibody to acetylcholine receptor in myasthenia gravis: investigation by plasma exchange. Neurology 28 (1978) 266-272
96. Okada K., Inoue A., Okada M., Murata Y., Kakuta S., Jigami T., Kubo S., Shiraishi H., Eguchi K., Motomura M., et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312 (2006) 1802-1805
97. O'Neill J.H., Murray N.M., and Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111 (1988) 577-596
98. Patrick J., and Lindstrom J. Autoimmune response to acetylcholine receptor. Science 180 (1973) 871-872
99. Peers C., Lang B., Newsom-Davis J., and Wray D.W. Selective action of myasthenic syndrome antibodies on calcium channels in a rodent neuroblastoma x glioma cell line. J. Physiol. 421 (1990) 293-308
100. Piddlesden S.J., Jiang S., Levin J.L., Vincent A., and Morgan B.P. Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J. Neuroimmunol. 71 (1996) 173-177
101. Pinto A., Gillard S., Moss F., Whyte K., Brust P., Williams M., Stauderman K., Harpold M., Lang B., Newsom-Davis J., et al. Human autoantibodies specific for the alpha1A calcium channel subunit reduce both P-type and Q-type calcium currents in cerebellar neurons. Proc. Natl. Acad. Sci. USA 95 (1998) 8328-8333
102. Pinto A., Iwasa K., Newland C., Newsom-Davis J., and Lang B. The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels. Muscle Nerve 25 (2002) 715-724
103. Plested C.P., Tang T., Spreadbury I., Littleton E.T., Kishore U., and Vincent A. AChR phosphorylation and indirect inhibition of AChR function in seronegative MG. Neurology 59 (2002) 1682-1688
104. Plomp J.J., and Molenaar P.C. Involvement of protein kinases in the upregulation of acetylcholine release at endplates of alpha-bungarotoxin-treated rats. J. Physiol. 493 (1996) 175-186
105. Plomp J.J., Van Kempen G.T., De Baets M.B., Graus Y.M., Kuks J.B., and Molenaar P.C. Acetylcholine release in myasthenia gravis: regulation at single end-plate level. Ann. Neurol. 37 (1995) 627-636
106. Poliak S., Salomon D., Elhanany H., Sabanay H., Kiernan B., Pevny L., Stewart C.L., Xu X., Chiu S.Y., Shrager P., et al. Juxtaparanodal clustering of Shaker-like K+ channels in myelinated axons depends on Caspr2 and TAG-1. J. Cell Biol. 162 (2003) 1149-1160
107. Polizzi A., Huson S.M., and Vincent A. Teratogen update: maternal myasthenia gravis as a cause of congenital arthrogryposis. Teratology 62 (2000) 332-341
108. Reid G., Scholz A., Bostock H., and Vogel W. Human axons contain at least five types of voltage-dependent potassium channel. J. Physiol. 518 (1999) 681-696
109. Riemersma S., Vincent A., Beeson D., Newland C., Hawke S., Vernet-der Garabedian B., Eymard B., and Newsom-Davis J. Association of arthrogryposis multiplex congenita with maternal antibodies inhibiting fetal acetylcholine receptor function. J. Clin. Invest. 98 (1996) 2358-2363
110. 2+ flux in a human small cell carcinoma line. Nature 317 (1985) 737-739
111. Rogers S.W., Andrews P.I., Gahring L.C., Whisenand T., Cauley K., Crain B., Hughes T.E., Heinemann S.F., and McNamara J.O. Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis. Science 265 (1994) 648-651
112. Roper J., and Schwarz J.R. Heterogeneous distribution of fast and slow potassium channels in myelinated rat nerve fibres. J. Physiol. 416 (1989) 93-110
113. Rothenberg S.P., da Costa M.P., Sequeira J.M., Cracco J., Roberts J.L., Weedon J., and Quadros E.V. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N. Engl. J. Med. 350 (2004) 134-142
114. Roxanis I., Micklem K., McConville J., Newsom-Davis J., and Willcox N. Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J. Neuroimmunol. 125 (2002) 185-197
115. Ruff R.L., and Lennon V.A. End-plate voltage-gated sodium channels are lost in clinical and experimental myasthenia gravis. Ann. Neurol. 43 (1998) 370-379
116. Safronov B.V., Kampe K., and Vogel W. Single voltage-dependent potassium channels in rat peripheral nerve membrane. J. Physiol. 460 (1993) 675-691
117. Sahashi K., Engel A.G., Linstrom J.M., Lambert E.H., and Lennon V.A. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis. J. Neuropathol. Exp. Neurol. 37 (1978) 212-223
118. Sahashi K., Engel A.G., Lambert E.H., and Howard Jr. F.M. Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J. Neuropathol. Exp. Neurol. 39 (1980) 160-172
119. Salmon A.M., Bruand C., Cardona A., Changeux J.P., and Berrih-Aknin S. An acetylcholine receptor alpha subunit promoter confers intrathymic expression in transgenic mice. Implications for tolerance of a transgenic self-antigen and for autoreactivity in myasthenia gravis. J. Clin. Invest. 101 (1998) 2340-2350
120. Sanes J.R., and Lichtman J.W. Development of the vertebrate neuromuscular junction. Annu. Rev. Neurosci. 22 (1999) 389-442
121. Scadding G.K., Vincent A., Newsom-Davis J., and Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology 31 (1981) 935-943
122. Schluep M., Willcox N., Vincent A., Dhoot G.K., and Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann. Neurol. 22 (1987) 212-222
123. Scuderi F., Marino M., Colonna L., Mannella F., Evoli A., Provenzano C., and Bartoccioni E. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab. Invest. 82 (2002) 1139-1146
124. Selcen D., Fukuda T., Shen X.M., and Engel A.G. Are MuSK antibodies the primary cause of myasthenic symptoms?. Neurology 62 (2004) 1945-1950
125. Serratrice G., and Azulay J.P. [What is left of Morvan's fibrillary chorea?]. Rev. Neurol. (Paris) 150 (1994) 257-265
126. Sheng M., Tsaur M.L., Jan Y.N., and Jan L.Y. Contrasting subcellular localization of the Kv1.2 K+ channel subunit in different neurons of rat brain. J. Neurosci. 14 (1994) 2408-2417
127. Sher E., Gotti C., Canal N., Scoppetta C., Piccolo G., Evoli A., and Clementi F. Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet 2 (1989) 640-643
128. Shi G., Nakahira K., Hammond S., Rhodes K.J., Schechter L.E., and Trimmer J.S. Beta subunits promote K+ channel surface expression through effects early in biosynthesis. Neuron 16 (1996) 843-852
129. Shigemoto K., Kubo S., Maruyama N., Hato N., Yamada H., Jie C., Kobayashi N., Mominoki K., Abe Y., Ueda N., and Matsuda S. Induction of myasthenia by immunization against muscle-specific kinase. J. Clin. Invest. 116 (2006) 1016-1024
130. Shillito P., Molenaar P.C., Vincent A., Leys K., Zheng W., van den Berg R.J., Plomp J.J., van Kempen G.T., Chauplannaz G., Wintzen A.R., et al. Acquired neuromyotonia: evidence for autoantibodies directed against K+ channels of peripheral nerves. Ann. Neurol. 38 (1995) 714-722
131. Shiono H., Wong Y.L., Matthews I., Liu J.L., Zhang W., Sims G., Meager A., Beeson D., Vincent A., and Willcox N. Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor. Int. Immunol. 15 (2003) 903-913
132. Shiraishi H., Motomura M., Yoshimura T., Fukudome T., Fukuda T., Nakao Y., Tsujihata M., Vincent A., and Eguchi K. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann. Neurol. 57 (2005) 289-293
133. Sinha S., Newsom-Davis J., Mills K., Byrne N., Lang B., and Vincent A. Autoimmune aetiology for acquired neuromyotonia (Isaacs' syndrome). Lancet 338 (1991) 75-77
134. Slater C.R., Fawcett P.R., Walls T.J., Lyons P.R., Bailey S.J., Beeson D., Young C., and Gardner-Medwin D. Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with "limb-girdle myasthenia". Brain 129 (2006) 2061-2076
135. Smart S.L., Lopantsev V., Zhang C.L., Robbins C.A., Wang H., Chiu S.Y., Schwartzkroin P.A., Messing A., and Tempel B.L. Deletion of the K(V)1.1 potassium channel causes epilepsy in mice. Neuron 20 (1998) 809-819
136. Sonoda Y., Arimura K., Kurono A., Suehara M., Kameyama M., Minato S., Hayashi A., and Osame M. Serum of Isaacs' syndrome suppresses potassium channels in PC-12 cell lines. Muscle Nerve 19 (1996) 1439-1446
137. Spreadbury I., Kishore U., Beeson D., and Vincent A. Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation. J. Neuroimmunol. 162 (2005) 149-156
138. Stanley E.F., and Drachman D.B. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions. Science 200 (1978) 1285-1287
139. Takamori M., Hamada T., Komai K., Takahashi M., and Yoshida A. Synaptotagmin can cause an immune-mediated model of Lambert-Eaton myasthenic syndrome in rats. Ann. Neurol. 35 (1994) 74-80
140. Takamori M., Takahashi M., Yasukawa Y., Iwasa K., Nemoto Y., Suenaga A., Nagataki S., and Nakamura T. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert-Eaton myasthenic syndrome. J. Neurol. Sci. 133 (1995) 95-101
141. Takamori M., Komai K., and Iwasa K. Antibodies to calcium channel and synaptotagmin in Lambert-Eaton myasthenic syndrome. Am. J. Med. Sci. 319 (2000) 204-208
142. Thieben M.J., Lennon V.A., Boeve B.F., Aksamit A.J., Keegan M., and Vernino S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 62 (2004) 1177-1182
143. Tomimitsu H., Arimura K., Nagado T., Watanabe O., Otsuka R., Kurono A., Sonoda Y., Osame M., and Kameyama M. Mechanism of action of voltage-gated K+ channel antibodies in acquired neuromyotonia. Ann. Neurol. 56 (2004) 440-444
144. Toyka K.V., Brachman D.B., Pestronk A., and Kao I. Myasthenia gravis: passive transfer from man to mouse. Science 190 (1975) 397-399
145. Traka M., Goutebroze L., Denisenko N., Bessa M., Nifli A., Havaki S., Iwakura Y., Fukamauchi F., Watanabe K., Soliven B., et al. Association of TAG-1 with Caspr2 is essential for the molecular organization of juxtaparanodal regions of myelinated fibers. J. Cell Biol. 162 (2003) 1161-1172
146. Tzartos S.J., Rand D.E., Einarson B.L., and Lindstrom J.M. Mapping of surface structures of electrophorus acetylcholine receptor using monoclonal antibodies. J. Biol. Chem. 256 (1981) 8635-8645
147. Tzartos S.J., Kokla A., Walgrave S.L., and Conti-Tronconi B.M. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the alpha subunit. Proc. Natl. Acad. Sci. USA 85 (1988) 2899-2903
148. Tzartos S.J., Barkas T., Cung M.T., Mamalaki A., Marraud M., Orlewski P., Papanastasiou D., Sakarellos C., Sakarellos-Daitsiotis M., Tsantili P., and Tsikaris V. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol. Rev. 163 (1998) 89-120
149. 2+ channels. Proc. Natl. Acad. Sci. USA 100 (2003) 3491-3496
150. Valenzuela D.M., Stitt T.N., DiStefano P.S., Rojas E., Mattsson K., Compton D.L., Nunez L., Park J.S., Stark J.L., Gies D.R., et al. Receptor tyrosine kinase specific for the skeletal muscle lineage: expression in embryonic muscle, at the neuromuscular junction, and after injury. Neuron 15 (1995) 573-584
151. Veh R.W., Lichtinghagen R., Sewing S., Wunder F., Grumbach I.M., and Pongs O. Immunohistochemical localization of five members of the Kv1 channel subunits: contrasting subcellular locations and neuron-specific co-localizations in rat brain. Eur. J. Neurosci. 7 (1995) 2189-2205
152. Vernino S., Low P.A., Fealey R.D., Stewart J.D., Farrugia G., and Lennon V.A. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N. Engl. J. Med. 343 (2000) 847-855
153. Vernino S., Ermilov L.G., Sha L., Szurszewski J.H., Low P.A., and Lennon V.A. Passive transfer of autoimmune autonomic neuropathy to mice. J. Neurosci. 24 (2004) 7037-7042
154. Verschuuren J.J., Dalmau J., Tunkel R., Lang B., Graus F., Schramm L., Posner J.B., Newsom-Davis J., and Rosenfeld M.R. Antibodies against the calcium channel beta-subunit in Lambert-Eaton myasthenic syndrome. Neurology 50 (1998) 475-479
155. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat. Rev. Immunol. 2 (2002) 797-804
156. Vincent A., Whiting P.J., Schluep M., Heidenreich F., Lang B., Roberts A., Willcox N., and Newsom-Davis J. Antibody heterogeneity and specificity in myasthenia gravis. Ann. N Y Acad. Sci. 505 (1987) 106-120
157. Vincent A., Buckley C., Schott J.M., Baker I., Dewar B.K., Detert N., Clover L., Parkinson A., Bien C.G., Omer S., et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 127 (2004) 701-712
158. Wang H., Kunkel D.D., Martin T.M., Schwartzkroin P.A., and Tempel B.L. Heteromultimeric K+ channels in terminal and juxtaparanodal regions of neurons. Nature 365 (1993) 75-79
159. Wang H., Kunkel D.D., Schwartzkroin P.A., and Tempel B.L. Localization of Kv1.1 and Kv1.2, two K channel proteins, to synaptic terminals, somata, and dendrites in the mouse brain. J. Neurosci. 14 (1994) 4588-4599
160. Waterman S.A. Voltage-gated calcium channels in autonomic neuroeffector transmission. Prog. Neurobiol. 60 (2000) 181-210
161. Waterman S.A., Lang B., and Newsom-Davis J. Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann. Neurol. 42 (1997) 147-156
162. Watson R., Jiang Y., Bermudez I., Houlihan L., Clover L., McKnight K., Cross J.H., Hart I.K., Roubertie A., Valmier J., et al. Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology 63 (2004) 43-50
163. Weinberg C.B., and Hall Z.W. Antibodies from patients with myasthenia gravis recognize determinants unique to extrajunctional acetylcholine receptors. Proc. Natl. Acad. Sci. USA 76 (1979) 504-508
164. Whiting P.J., Vincent A., and Newsom-Davis J. Myasthenia gravis: monoclonal antihuman acetylcholine receptor antibodies used to analyze antibody specificities and responses to treatment. Neurology 36 (1986) 612-617
165. Wilson S., Vincent A., and Newsom-Davis J. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. I. Receptor degradation. J. Neurol. Neurosurg. Psychiatry 46 (1983) 377-382
166. Wilson S., Vincent A., and Newsom-Davis J. Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis. J. Neurol. Neurosurg. Psychiatry 46 (1983) 383-387
167. Xu W., Gelber S., Orr-Urtreger A., Armstrong D., Lewis R.A., Ou C.N., Patrick J., Role L., De Biasi M., and Beaudet A.L. Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proc. Natl. Acad. Sci. USA 96 (1999) 5746-5751
168. Yamamoto T., Vincent A., Ciulla T.A., Lang B., Johnston I., and Newsom-Davis J. Seronegative myasthenia gravis: a plasma factor inhibiting agonist-induced acetylcholine receptor function copurifies with IgM. Ann. Neurol. 30 (1991) 550-557
169. Yoshikawa H., Sato K., Edahiro S., Furukawa Y., Maruta T., Iwasa K., Watanabe H., Takaoka S., Suzuki Y., Takamori M., and Yamada M. Elevation of IL-12 p40 and its antibody in myasthenia gravis with thymoma. J. Neuroimmunol. 175 (2006) 169-175